ENV-294

Phase 2Small molecule

EEnveda Therapeutics

ENV-294 is one of 69 small molecule programs targeting Atopic Dermatitis (AD). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atopic Dermatitis (AD)Recruiting

Atopic DermatitisRecruiting

AsthmaRecruiting

Atopic Dermatitis (AD)Phase 2

Recruiting

Atopic DermatitisPhase 2

Recruiting

AsthmaPhase 2

Recruiting

Competition

Competitive Landscape

175 competitors in Asthma

#DrugCompanyPhaseTrials

Celexa

AbbVie

Preclinical

1 2

ENV-294

EEnveda Therapeutics

Phase 2

1 3

Arcoxia

Novartis

Preclinical

—4

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 5

DUPIXENT

Regeneron

Preclinical

1 6

Paracetamol

GSK

Preclinical

1 7

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 8

Aclidinium Bromide

AstraZeneca

Preclinical

—9

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 10

Lexapro

SShirley Ryan AbilityLab

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Atopic Dermatitis (AD)

NCT07298395

Q1 2027

Phase 2Recruiting

Asthma

NCT07301255

Q2 2028

Phase 2Recruiting

Atopic Dermatitis

NCT07643766

Clinical

Trials by Indication[1]

Atopic Dermatitis2 trials

Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis

Active, not recruiting·EEnveda Therapeutics·Phase 1·NCT07336940·16 enrolled

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

Recruiting·EEnveda Therapeutics·Phase 2·NCT07643766·200 enrolled

Asthma1 trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ENV-294 in Adult Participants With Moderate-to-Severe Asthma

Recruiting·EEnveda Therapeutics·Phase 2·NCT07301255·50 enrolled

Atopic Dermatitis (AD)1 trial

Recruiting·EEnveda Therapeutics·Phase 2·NCT07298395·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ENV-294. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ENV-294 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ENV-294. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Enveda Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEnveda Therapeutics

ENV-294

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2028

Trials by Indication[1]

Atopic Dermatitis2 trials

Asthma1 trial

Atopic Dermatitis (AD)1 trial

References

Drug Info

Quick Facts

Related News